The World Molecular Imaging Society (WMIS) presented its 2018 Commercial Innovation of the Year award to Netherlands-based molecular imaging company MILabs BV for its VECTor-6 Broadband Photon Tomography technique. Broadband photon tomography, as implemented on MILabs’ VECTor6 platform, expands the versatility and performance of preclinical imaging systems. For the first time, it is possible to perform nuclear and optical molecular imaging techniques on a single platform, enhanced by diagnostic and molecular x-ray computed tomography (CT). Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) images can now be acquired at unprecedented high resolutions, even for PET isotopes that exhibit positron ranges of several millimeters, such as 82Rb and 124I, while optical images can be visualized in 3D. Moreover, multiple PET isotopes, as well as co-injected PET/SPECT tracers, can be imaged simultaneously, and 3D optical/CT images can be obtained with single acquisitions. By imaging a photon energy range from 1 eV to 1 MeV, the capabilities of broadband photon tomography are expected to extend the application reach of in vivo animal imaging beyond the capabilities of current preclinical PET, SPECT, optical, and CT systems. “It’s great that this award brings the VECTor-6 platform in the spotlight so that both academics and pharmaceutical industry researchers can become aware that new imaging options are now available that extend applications beyond the capabilities of conventional PET, SPECT, optical, and CT imaging,” said Frederik Beekman, CEO of MILabs. “My team is very proud and happy about this recognition and the fact they are contributing to potentially raising biomedical research to new levels by building top-of-the-line instruments.” WMIS is an industry organization dedicated to developing and promoting translational research through multimodality molecular imaging. MILabs is a developer of molecular imaging techniques, focusing on preclinical PET, SPECT, CT, and optical imaging systems, along with human SPECT scanners.